Conformational analysis of geometric isomers of pitavastatin together with their lactonized analogues
- PMID: 24169468
- PMCID: PMC6270003
- DOI: 10.3390/molecules181113283
Conformational analysis of geometric isomers of pitavastatin together with their lactonized analogues
Abstract
Super-statins are synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, which is the rate-limiting enzyme responsible for the biosynthesis of cholesterol. All of the super-statins with a C=C double bond spacer between the heterocyclic and the dihydroxycarboxylic moiety that are currently on the market exist as E-isomers. To extend the understanding of conformational and thermodynamic preferences of Z-isomeric super-statin analogues, this study focused on analyzing pitavastatin and its lactonized derivatives via NMR spectroscopy and ab initio calculations. Z-isomeric pitavastatin analogues exist in solution as a pair of interconverting rotamers, where the Gibbs free energies between the major and minor rotamers are within 0.12 and 0.25 kcal mol-1 and the rotational energy barriers are between 15.0 and 15.9 kcal mol-1. The analysis of long-range coupling constants and ab initio calculations revealed that rotation across the C5'-C7 single bond is essential for generating a pair of atropisomers. The overall comparison of the results between Z-isomeric pitavastatin and rosuvastatin analogues demonstrated that the former are to some extent more flexible to attain numerous conformations. Demonstrating how structural differences between super-statin analogues induce distinctive conformational preferences provides important insight into the super-statins' conformational variability and may well improve future drug design.
Figures
 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                References
- 
    - Časar Z. Historic overview and recent advances in the synthesis of super-statins. Curr. Org. Chem. 2010;14:816–845. doi: 10.2174/138527210791111858. - DOI
 
- 
    - Fuenfschilling P.C., Pascale H., Mutz J.-P. An improved manufacturing process for fluvastatin. Org. Process Res. Dev. 2007;11:13–18. doi: 10.1021/op060191b. - DOI
 
- 
    - Roth B.D., Blankley C.J., Chucholowski A.W., Ferguson E., Hoefle M.L., Ortwine D.F., Newton R.S., Sekerke C.S., Sliskovic D.R., Stratton C.D., et al. Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran 2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus. J. Med. Chem. 1991;34:357–366. doi: 10.1021/jm00105a056. - DOI - PubMed
 
- 
    - Watanabe M., Koike H., Ishiba T., Okada T., Sea S., Hirai K. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg. Med. Chem. 1997;5:437–444. doi: 10.1016/S0968-0896(96)00248-9. - DOI - PubMed
 
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
- Miscellaneous
 
        